72 related articles for article (PubMed ID: 11212263)
41. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.
Zhu CQ; Shih W; Ling CH; Tsao MS
J Clin Pathol; 2006 Aug; 59(8):790-800. PubMed ID: 16873561
[TBL] [Abstract][Full Text] [Related]
42. Cyclin D1, cyclin E, and p21 have no apparent prognostic value in anal carcinomas treated by radiotherapy with or without chemotherapy.
Allal AS; Gervaz P; Bründler MA
Br J Cancer; 2004 Oct; 91(7):1239-44. PubMed ID: 15292923
[TBL] [Abstract][Full Text] [Related]
43. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
[TBL] [Abstract][Full Text] [Related]
44. Building an outcome predictor model for diffuse large B-cell lymphoma.
Sáez AI; Sáez AJ; Artiga MJ; Pérez-Rosado A; Camacho FI; Díez A; García JF; Fraga M; Bosch R; Rodríguez-Pinilla SM; Mollejo M; Romero C; Sánchez-Verde L; Pollán M; Piris MA
Am J Pathol; 2004 Feb; 164(2):613-22. PubMed ID: 14742266
[TBL] [Abstract][Full Text] [Related]
45. Association of over-expressed TFDP1 with progression of hepatocellular carcinomas.
Yasui K; Okamoto H; Arii S; Inazawa J
J Hum Genet; 2003; 48(12):609-613. PubMed ID: 14618416
[TBL] [Abstract][Full Text] [Related]
46. Human HTm4 is a hematopoietic cell cycle regulator.
Donato JL; Ko J; Kutok JL; Cheng T; Shirakawa T; Mao XQ; Beach D; Scadden DT; Sayegh MH; Adra CN
J Clin Invest; 2002 Jan; 109(1):51-8. PubMed ID: 11781350
[TBL] [Abstract][Full Text] [Related]
47. Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer.
Sterlacci W; Fiegl M; Tzankov A
Pathobiology; 2012; 79(4):175-94. PubMed ID: 22441109
[TBL] [Abstract][Full Text] [Related]
48. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas.
Dobashi Y; Jiang SX; Shoji M; Morinaga S; Kameya T
J Pathol; 2003 Feb; 199(2):208-20. PubMed ID: 12533834
[TBL] [Abstract][Full Text] [Related]
49. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors.
Schmidt BA; Rose A; Steinhoff C; Strohmeyer T; Hartmann M; Ackermann R
Cancer Res; 2001 May; 61(10):4214-21. PubMed ID: 11358847
[TBL] [Abstract][Full Text] [Related]
50. [The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)].
Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Jankowska R
Pol Merkur Lekarski; 2011 Apr; 30(178):253-8. PubMed ID: 21595169
[TBL] [Abstract][Full Text] [Related]
51. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
[TBL] [Abstract][Full Text] [Related]
52. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
[TBL] [Abstract][Full Text] [Related]
53. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.
Müller-Tidow C; Metzger R; Kügler K; Diederichs S; Idos G; Thomas M; Dockhorn-Dworniczak B; Schneider PM; Koeffler HP; Berdel WE; Serve H
Cancer Res; 2001 Jan; 61(2):647-53. PubMed ID: 11212263
[TBL] [Abstract][Full Text] [Related]
54. E- and A-type cyclins as markers for cancer diagnosis and prognosis.
Yasmeen A; Berdel WE; Serve H; Müller-Tidow C
Expert Rev Mol Diagn; 2003 Sep; 3(5):617-33. PubMed ID: 14510182
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
